Ministry of Health care. Regional state control over the application of prices for essential drugs List of vital drugs on

1. Approve:

list of vital and essential drugs for medical use for 2016 according to Appendix No. 1;

a list of medications for medical use, including medications for medical use prescribed by decision of medical commissions of medical organizations, in accordance with Appendix No. 2;

a list of medications intended to provide persons with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, persons after organ and (or) tissue transplantation, in accordance with Appendix No. 3;

the minimum range of medications necessary to provide medical care, in accordance with Appendix No. 4.

2. Establish that until March 1, 2016, the list of vital and essential drugs for medical use for 2015, approved by Decree of the Government of the Russian Federation of December 30, 2014 N 2782-r, is applied.

3. Decree of the Government of the Russian Federation dated December 30, 2014 No. 2782-r (Collected Legislation of the Russian Federation, 2015, No. 3, Art. 597) is declared invalid.

Chairman of the Government

Russian Federation

To control the circulation of medicines, not only a register of vital and essential medicines was created, but also a Register of maximum selling prices for vital and essential drugs (2020). Let's take a closer look at both registries. In order to find out the maximum wholesale and retail price of the drug of interest, open the excel file.

VED, transcript

Vital and essential drugs (VED, until 2011 the abbreviation “VED” was used, or Vital and essential drugs) is a list of drugs approved by the Government of the Russian Federation for the purpose of state regulation of drug prices. This is done to increase their accessibility for the population and medical institutions.

The VED list contains a list of medicines under international nonproprietary names and covers almost all types of medical care provided to citizens of the Russian Federation within the framework of state guarantees, in particular, emergency medical care, hospital care, specialized outpatient and inpatient care, and also includes a significant amount medicines sold in the commercial sector.

In addition, the List of Vital and Essential Medicines serves as the basis for the development of regional lists of constituent entities of the Russian Federation and formulary lists of medicines for inpatient medical organizations.

All information can be easily obtained online, including the VED registry for 2020 - the official website is a section on the website of the Ministry of Health.

You just need to fill out the fields and click “Find”.

Maximum permissible price

State regulation of the cost of drugs from the list of vital and essential drugs has been carried out since 2010.

Control is carried out at the following levels:

1. The Ministry of Health of the Russian Federation fixes the maximum selling prices of VED manufacturers. More expensive factories cannot sell medicines to wholesale and retail trade. The cost of a medicine depends on the cost of packaging materials, medicinal substances, etc. Since a number of medicines and substances are imported, their cost is affected by changes in exchange rates.
2. In each subject of the Russian Federation, the maximum amounts of wholesale and retail markups are established. Allowances serve to reimburse associated trade costs for the sale of medications: delivery, storage, rental of premises, wages for pharmacists. The markups they apply cannot exceed the maximum established markups to the manufacturer's cost. Thus, in the Tyumen region, the amount of retail markups, for example, for drugs in the price category of 50-500 rubles, is limited to 25%. For comparison, in the constituent entities of the Ural Federal District the maximum level of retail markups is set in the range of 27-70%.

The final cost, which we see on the price tag at the pharmacy, consists of:

• the actual price of the manufacturer, not exceeding the established limit;
• wholesale markup to the manufacturer's actual price;
• retail premium to the manufacturer's price.

Thus, the state limits the maximum cost of vital and essential drugs, above which no pharmacy can sell such a drug. All pharmacy organizations post information about medications, indicating names, dosages, release forms, manufacturers, as well as the maximum permissible retail price at which they can be sold, so every buyer can find out. The placement of this information is regulated by the federal law “On the Circulation of Medicines” dated April 12, 2010 No. 61-FZ (clause 3 of Article 63).

Maximum permissible prices for vital and essential drugs 2020

The register of maximum selling prices for vital and essential drugs 2020 can be found on the website of the Ministry of Health.

In addition, the current list of products and their prices can be downloaded at the end of the article as an excel file.

Operational monitoring of prices for vital drugs by Roszdravnadzor is carried out in the same place where the register of vital drugs for 2020 is located - the official website of the Ministry of Health posts this information in a special section. The purpose of the monitoring is to check the assortment and pricing policy of clinics and pharmacies. Monitoring vital and essential drugs is the responsibility of medical and pharmacy organizations of any form of ownership. Every month, before the 25th day, a report is prepared that lists stocks on the 15th day of the reporting period for drugs from the list of vital and essential drugs.

Order of the Government of the Russian Federation of October 23, 2017 N 2323-r On approval of the list of vital and essential drugs for 2018, the list of drugs for medical use, the list of drugs intended to provide people with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, as well as persons after organ and (or) tissue transplantation, as well as the minimum range of medications necessary to provide medical care (repealed)

Appendix No. 1. List of vital and essential medicines for medical use for 2018 Appendix No. 2. List of medicines for medical use, including medicines for medical use prescribed by decision of medical commissions of medical organizations Appendix No. 3. List of medicines drugs intended to provide persons with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, as well as persons after organ and (or) tissue transplantation Appendix No. 4. Minimum range of drugs necessary to provide medical care

1. Approve:

list of vital and essential drugs for medical use for 2018 according to Appendix No. 1;

a list of medications for medical use, including medications for medical use prescribed by decision of medical commissions of medical organizations, in accordance with Appendix No. 2;

a list of medications intended to provide persons with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, as well as persons after organ and (or) tissue transplantation, in accordance with Appendix No. 3;

the minimum range of medications necessary to provide medical care, in accordance with Appendix No. 4.

2. Decree of the Government of the Russian Federation dated December 26, 2015 No. 2724-r (Collected Legislation of the Russian Federation, 2016, No. 2, Art. 413) is declared invalid.

The list of vital and essential drugs (VED) for medical use for 2018 has been approved. Compared to the list of VED for 2017, the new list has been supplemented with new drugs and dosage forms.

A new list of drugs has also been approved to provide benefits to categories of citizens, a list of expensive drugs under the “7 nosologies” program (“orphan” drugs) to provide people with hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, malignant neoplasms of the lymphoid, hematopoietic and related tissues, multiple sclerosis, as well as persons after organ and (or) tissue transplantation.

Details Created: 01/09/2017

Head of the Government of the Russian Federation Dmitry Medvedev signed order No. 2885-r on approval of the list of vital and essential drugs (VED) for medical use for 2017. The new list of vital and essential drugs is similar to the list of such drugs for 2016.

D.Medvedev: I signed a government order that approves the list of vital and essential medications for the next year, 2017. This is a voluminous document.

The government approves such a list annually. It is aimed at controlling the prices of drugs on this list, so that there is no speculation of any kind and, most importantly, that these drugs remain affordable to everyone who purchases them.

Recently, the list began to be formed more openly, with the direct participation of the professional community. I hope this will allow us to better understand which drugs are really in demand, what is happening with pricing, and how well the regions are provided with this or that drug. Prices for medicines and health care problems, according to sociological surveys, remain one of the most significant topics for almost any Russian family. Olga Yuryevna (addressing O. Golodets), please say a few more words about this list.

O. Golodets: Indeed, over the past two years, the list of vital and essential medicines has been significantly expanded, with 96 new items included. In total, it contains 646 international non-proprietary names, and it fully guarantees the provision of medicinal care.

D. Medvedev: International Nonproprietary Names are essentially a chemical formula, and drug names can be different because they are made by different suppliers, sometimes with some additives. In short, there are more drugs than chemical names.

O. Golodets: Since 2014, a new procedure has been established for creating a list of these drugs, which ensures maximum openness and involvement of the expert community. 46 expert institutions participate in the work of the commission, which operates under the Ministry of Health. This ensures objective and scientific reliability of the decisions made.

An important trend in recent years is the increase in the share of domestic drugs in the list of vital and essential drugs. As a result of the growth of the Russian pharmaceutical industry and the implementation of the import substitution program, the share of domestic drugs in the last year alone has increased from 72% in 2015 to 76.8% in 2016.

In addition to the fact that we are now registering domestic drugs that already exist on the market, we have included several innovative drugs in the VED that are not on the world market, and their manufacturers are domestic companies. This is a serious step in the development of the domestic pharmaceutical industry.

Next year, at the request of pharmaceutical manufacturers, the list of vital and essential drugs will be approved not once a year, as is happening now, but as new drugs become available. We expect serious drugs to enter the market that will help in the fight against cancer and some orphan diseases. They are currently undergoing clinical trials and are already at a high level of readiness. I hope that the mechanisms that have been put in place will significantly increase access to medicines on the Russian market.

D. Medvedev: The fact that changes to the Vital and Essential Drugs list will be approved more often is really good for the cause, because when a drug appears, it’s good if it immediately gets there and becomes available to citizens. We will act this way.

List of vital and essential drugs for medical use for 2017 (approved by Decree of the Government of the Russian Federation of December 28, 2016 N 2885-r)

• Back
• Forward

Preferential drug provision. Documentation

Order of the Government of the Russian Federation dated October 12, 2019 N 2406-r

Register of regional beneficiaries living in the Republic of Crimea. (Order of the Ministry of Health of the Republic of Kazakhstan No. 1289 dated August 19, 2015)

Classifier of certain categories of citizens entitled to receive medicinal assistance on preferential terms. Appendix No. 1 to the order of the Ministry of Health of the Republic of Kazakhstan dated 03.11.2015 No. 1777

Order of the Ministry of Health of the Republic of Crimea dated June 26, 2016 No. 770 “On approval of the list of pharmacies and pharmacy points of the State Unitary Enterprise of the Republic of Kazakhstan “Crimea-Pharmacia” for the dispensing of preferential medications, drugs of high-cost nosologies, insulin-containing drugs”

Resolution of the Council of Ministers of the Republic of Kazakhstan No. 38 dated 07/07/15. “On the procedure for implementing organizational measures in the territory of the Republic of Crimea to provide individuals with medications intended for the treatment of patients with malignant neoplasms of lymphoid, hematopoietic and related tissues, hemophilia, cystic fibrosis, pituitary dwarfism, Gaucher disease, multiple sclerosis, as well as after organ transplantation and ( or) fabrics"

Prime Minister Dmitry Medvedev approved the list of vital and essential drugs for medical use (VED) for 2018. The corresponding order, prepared by the Ministry of Health, was published on the Government website on October 23.

Government Order No. 2323 r dated October 23, 2017 approved lists of vital and essential drugs, drugs prescribed by decision of the medical commission, drugs from the “7 nosologies” program, as well as a list of the minimum range of drugs.

Summary table of new INNs included in the list of VEDs for 2018

Materials about Vital and Essential Drugs and other lists: